Seminar
Tuesday, April 9, 2019 - 12:00am
Graduate Student Chengshuo "Jason" Tian will present
"Polymeric Nanocapsules for Drug Delivery"
on April 9, 2019 at 4:10pm in Neville Hall, room 3
Nanoparticle drug delivery systems are known to include nanospheres, micelles, solid lipid nanoparticles, nanoliposomes, dendrimers, magnetic nanoparticles and nanocapsules that have the great potential to treat difficult diseases.[1] Nanocapsules are one of the most well developed vesicle systems consisting of an internal core surrounded by polymer walls. Nanocapsules have great potential as drug carriers due to many advantages, such as improved water solubility and stabilization of the drug from the environment by protecting molecules. It provides the desired pharmacokinetic profile, with controlled release.
Monoclonal antibodies (mAbs) have become a potent therapeutic agent for the treatment of a variety of diseases. However, for Central Nervous System (CNS) diseases, delivery of mAb therapeutic agents into the central nervous system is extremely difficult due to limitations of the Brain–Blood Barrier (BBB). Recently, monoclonal antibody-based nanocapsules have been reported to treat brain tumors.[2] This delivery strategy is based on the encapsulation of mAbs in nanocapsules containing choline and acetylcholine analogs. These analogs promote the BBB penetration of nanocapsules and delivery of mAbs to tumor sites.
Protein therapy, in which therapeutic proteins are delivered to treat disease, is considered to be the safest and most direct method of treating disease. However, its use is limited by the lack of effective protein delivery strategies and the rapid clearance of therapeutic proteins in vivo after administration. It has been reported that a novel nanocapsule made of a thin layer of cross-linked phosphorylcholine polymer is effective in preventing encapsulation of proteins from being phagocytosed by macrophages.[3]
References
[1] H. Khodabandehloo, et al., Iran J Cancer Prev. 2016 April; 9(2): e3966.
[2] L. Han, et al., Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy, Adv. Mater. 2019, 1805697
[3] S. Liang, et al., Phosphorylcholine polymer nanocapsules prolong the circulation time and reduce the immunogenicity of therapeutic proteins, Nano Res. 2016, 9(4): 1022–1031